Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Akt kinase plays a critical role in cellular processes such as growth, survival, metabolism, and migration.
• Dysregulation of Akt signaling pathways is frequently observed in various cancers and metabolic diseases.
• Overactivation of Akt signaling contributes to uncontrolled cell proliferation and survival in cancerous cells.

Purpose of the Study:

• To review the landscape of Akt inhibitors for therapeutic applications.
• To discuss the classification and mechanisms of different Akt inhibitor types.
• To highlight recent advancements and future directions in Akt inhibitor development for cancer therapy.

Main Methods:

• Review of existing literature on Akt kinase signaling and inhibitors.
• Classification of Akt inhibitors based on their binding mechanisms (ATP-competitive, allosteric, covalent-allosteric).
• Analysis of clinical applications and challenges associated with Akt inhibitor therapies.

Main Results:

• Akt inhibitors are categorized into ATP-competitive, allosteric, and covalent-allosteric inhibitors (CAAIs).
• Capivasertib (AZD5363), an ATP-competitive inhibitor, gained FDA approval for breast cancer treatment.
• Covalent-allosteric inhibitors show potential for enhanced potency and selectivity.

Conclusions:

• Akt inhibitors represent a significant therapeutic strategy for targeting cancers with dysregulated Akt signaling.
• Further research is needed to enhance inhibitor selectivity, identify predictive biomarkers, and minimize side effects.
• Covalent-allosteric inhibitors offer promising avenues for developing more effective and personalized cancer treatments.